Anti-Human CD9 FITC

Description: The eBioSN4 monoclonal antibody reacts with human CD9. CD9 is a 24 kDa member of the tetraspanin family, whose members are characterized by the presence of 4 hydrophobic transmembrane domains. CD9 is expressed in platelets, eosinophils, basophils, pre-B cells, activated T cells and neural cell lines. Furthermore, CD9 expression has been associated with a malignant phenotype, including expression on 90% of non T cell acute lymphoblastic leukemia cells and on 50% of chronic lymphocytic and acute myeloblastic leukemias. In platelets, CD9 is expressed in α-granules and through association with the integrin αIIb/βIII plays a role in platelet aggregation, as demonstrated by the use of anti-human CD9 antibodies. CD9 has also been shown to induce the aggregation of pre-B cell lines, and the adhesion and migration of pre-B cells and Schwann cells. Additionally, it has been demonstrated that CD9 is able to provide a co-stimulatory signal for T cells independently of CD28, in the absence of antigen-presenting cells. Binding of the eBioSN4 monoclonal antibody partially cross-blocks binding of another anti-human CD9 monoclonal antibody, MM2/57.

References: Luo Y, Hara H, Haruta Y, Seon BK. Establishment of ascitic tumor of human pre-B acute lymphoblastic leukemia in nonconditioned nude mice. Cancer Res. 1989 Feb 1;49(3):706-10. (SN4, PubMed)

Ito T, Inaba M, Inaba K, Toki J, Sogo S, Iguchi T, Adachi Y, Yamaguchi K, Amakawa R, Valladeau J, Saeland S, Fukuhara S, Ikehara S. A CD1a+/CD11c+ subset of human blood dendritic cells is a direct precursor of Langerhans cells. J Immunol. 1999 Aug 1;163(3):1409-19.